The board of directors of Biohaven Pharmaceuticals recently elected CEO Vlad Coric to the role of board chairman, following the retirement of Declan Doogan.
Meanwhile, Matthew Buten will be the company’s new chief financial officer as of Dec. 20. He is replacing James Engelhart, who is retiring.
Buten is a former managing director of Foresite Capital with more than 20 years of experience in healthcare investing as well as 15 plus years as an advisor in investment banking.